Introduction
Botulinum neurotoxin type A (BoNT/A) is a leading tool in the treatment of neuromuscular diseases and has also been used for cosmetic purposes for a long time. During immunogenic responses, "neutralizing" antibodies develop against the toxin, inhibiting the interaction between BoNT/A and its presynaptic membrane binding site, [1] [2] [3] causing an inadequate or no response to BoNT/A. 4 BoNT/A products, especially new toxin formulations, typically undergo rigorous evaluations for use as prescription-only medicines. Clinicians should, therefore, select less immunogenic, highly purified toxins to obtain successful results for long-term repeated treatments. Frevert et al New toxin formulations have recently emerged in Asia but investigations to quantify these neurotoxins such as their purity (defined as being complexing protein-free), the impact of their dose on efficacy, or adverse events, have been limited. 6 Therefore, we analyzed the composition of the neurotoxin component of each product relative to Xeomin ® using a sandwich enzyme-linked immunosorbent assay (ELISA) with antisera directed against the purified BoNT/A, to better understand these newer formulations. We seek to provide clinicians with valuable information to enable safe and effective treatment with BoNT/A. (Table 1) . Because the manufacturing process for a biologic therapeutic should be consistent and every batch should be representative, the batches were, therefore, selected arbitrarily. The batches were purchased from a South Korean pharmacy (ShinOn Pharmacy Co. Ltd., Seoul, South Korea). Care was taken to transport and store the samples at 2°C-8°C, except samples of Xeomin that can be stored at room temperature. The composition of the neurotoxin elements of each product compared to those of Xeomin was then analyzed in duplicate to determine the mean amount of neurotoxin protein.
Materials and methods Materials

Methods
All analyses were carried out with an ELISA approved by the FDA (Food and Drug Administration, Silver Spring, MD, USA) and several other health authorities. The facility in which samples were analyzed was inspected by the FDA regularly and fulfilled current good manufacturing practice requirements.
For incubation, PBS + 0.1% bovine serum albumin (solution 1) and PBS + 6% gelafusal (Serumwerke Bernburg, Bernburg, Germany; solution 2) (Merck, Darmstadt, Germany, or Riedel-de-Haen, Seelze, Germany) were used. Additional reagents included O-phenylenediamine dihydrochloride (Sigma-Aldrich Corp, St. Louis, MO, USA) and horse anti-serum reacting with the neurotoxin complex of BoNT/A (UK National Institute for Biological Standards and Control, NIBSC). Following a modified protocol, 7 the 150 kDa neurotoxin purified from the "Hall Strain", C. botulinum type A, strain ATCC 3502, was confirmed by western blot as complexing protein-free and detoxified by 0.4% formaldehyde treatment to produce the nontoxic antigen for antibody preparation. Complexing proteins (excluding the botulinum neurotoxin protein) were prepared as previously published. 8 The purified toxin was dialyzed against 50 mM TRIS (tris[hydroxymethyl] aminomethane)/HCl pH = 7.9, Q-sepharose column chromatography-purified (GE Healthcare, Munich, Germany) and column-bound complexing proteins were eluted. Antibodies against BoNT/A were immobilized on a CNBr sepharose matrix (GE Healthcare). BoNT/A was removed through affinity chromatography, eluted, and its composition checked for integrity.
ELISA
The amount of BoNT/A in pharmaceutical formulations of Botulax, Meditoxin, Nabota, or Relatox was measured in 8 for representative standard curves). Internal controls were performed for each plate to ensure assay validity. Standard curve linearity and ELISA specificity, accuracy, and robustness were performed according to International Conference on Harmonisation guidelines. 9 The ELISA was shown to be specific for the BoNT/A neurotoxin and did not detect complexing proteins. Table 1 describes the properties of Innotox, Botulax, Meditoxin, Nabota, and Relatox. 10 Highly sensitive sandwich ELISA was used to quantify the amount of BoNT/A protein in Botulax, Meditoxin, Nabota, and Relatox (Table 2) . Xeomin was independently analyzed in parallel as a control and found to have a mean toxin content of 416 pg/vial, comparable to reports from another batch. 8 It should be noted that this variation from published values is due to these batches of toxin being no longer available for the present analysis and the use of a different batch of Xeomin, as well as a 5% intervial variability during the manufacturing process (unpublished data 2018, Merz Pharmaceuticals GmbH).
Results
Botulax and Nabota contained 844 and 754 pg of neurotoxins, respectively, which are nearly twice the neurotoxin content of Xeomin (416 pg) in an equivalent 100 U vial. However, the percentage of inactive neurotoxins was also calculated to be much higher at 103 and 81, respectively, than that of Xeomin with no inactive neurotoxin. The potency per pg of neurotoxin in Botulax and Nabota was found to be 0.118 and 0.133 U, respectively. This was less potent than Xeomin's 0.240 U per pg of neurotoxin. Meditoxin and Relatox contained 575 and 578 pg of neurotoxins, respectively, which were slightly higher than that of the Xeomin, as was the calculated percentage of inactive neurotoxins at 38 and 33, respectively. The efficacy per pg of neurotoxin in Meditoxin and Relatox was found to be 0.174 and 0.173 U, respectively, which were also lower than Xeomin's 0.240 U of efficacy per pg of neurotoxin.
Discussion
All BoNT/A formulations contain the 150 kDa neurotoxin, which is the active molecule. Xeomin, however, consists solely of the 150 kDa neurotoxin. All products are based on the botulinum toxin complex with about sixfold more additional bacterial proteins, assuming a molecular weight of ≈900 kDa for the complex. Some of the complexing proteins 
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Frevert et al are hemagglutinins, which are glycoprotein binding proteins (so-called lectins). In contrast to the 150 kDa neurotoxin, these complexing proteins have the potential to bind to dendritic cells, 11, 14 the sentinel cells of the immune system. These cells must be activated as the first step of the initiation of an immune response. 12, 14 In this regard, complexing protein-containing products have a higher potential to cause an immune response. Indeed, the formation of antibodies in patients treated with complexing protein-containing products in esthetic medicine has been reported. 7 In contrast, antibody formation was not observed in patients treated with Xeomin free of complexing proteins. A further important factor determining the potential for immunogenicity of BoNT/A formulations and subsequent treatment failure is the amount of neurotoxin protein present. 5, 15 This is associated with increased antigen levels and, consequently, a greater risk of antibody production. 16 It was demonstrated in cervical dystonia patients treated with BoNT products that the specific potency (U per pg neurotoxin) is correlated with the antibody-induced therapy failure. 17 It is, therefore, helpful for the clinician to receive information about the specific potency of different botulinum toxin products.
Currently, BoNT/A preparations approved for several indications in adults in Asia, Europe, and the USA include onabotulinumtoxinA (Allergan Inc., Irvine, CA, USA; also known as Botox ® or Vistabel ® ), abobotulinumtoxinA (Ipsen Ltd, Slough, UK/Galderma, Paris, France; also known as Dysport ® or Azzalure ® ), and incobotulinumtoxinA (Merz Pharmaceuticals GmbH, Reinheim, Germany; also known as Xeomin or Bocouture ® ), each of which is uniquely formulated. These variable manufacturing, formulation, and testing processes have produced preparations with different potency, dosage, constituents, and immunogenicity. 18, 19 As Xeomin's manufacturing process isolates only the active 150 kDa neurotoxin, Xeomin is entirely free of complexing protein. 20 Besides the active 150 kDa neurotoxin, Botox and Dysport contain complexing proteins that form a high-molecular-weight complex with the 150 kDa neurotoxin. That is, Botox comprises one 150 kDa neurotoxin molecule within a 900 kDa protein complex. 21 Although Dysport's precise biochemical composition remains undefined, it is also likely to contain the 500-600 kDa L-complex protein within the 900 kDa complex protein as well. 22 Xeomin/Bocouture remains the only BoNT/A product marketed as containing "purified neurotoxin" that has been registered with regulatory authorities in the USA and Europe.
As reported, Botox contains 5,000 pg of toxin per 100 U vial 23 (including complexing proteins), Dysport contains 4,350 pg of toxin (including complexing proteins) per 500 U vial, 24 and Xeomin contains 440 pg of neurotoxin per 100 U vial. 8 Here, the mean concentration of BoNT/A neurotoxin was 730 pg in a 100 U vial of Botox (batches C2344C3, C2384C3, C2419, and C2385), 650 pg in a 100 U vial of Dysport (batches 678F and 689X), and 440 pg in 100 U vials of Xeomin (batches 61,111, 70,604, and 81,208). 8 The specific potency, defined as the potency in units associated with a specified amount of the 150 kDa toxin in each product, was 0.137 U/pg for Botox, 0.154 U/pg for Dysport, and 0.227 U/pg for Xeomin, 8 which suggested that Xeomin was the most potent because it has the highest amount of toxin protein among those tested.
Comparing the different products, Botulax and Nabota showed a similar specific potency with 0.118 and 0.133 U/ pg, respectively. Meditoxin and Relatox have less neurotoxin protein than Botulax and Nabota but higher specific potencies (0.174 and 0.173 U/pg). However, their specific potencies are lower than that of Xeomin (0.240 U/pg). One can conclude that the lower specific potency of Botulax, Nabota, Meditoxin, and Relatox may actually indicate the presence of significant amounts of inactive, rather than active, neurotoxin. Thus, high neurotoxin protein levels detected in this study were not due to biologically efficacious neurotoxin, but due to inactive toxin provided that all products were equipotent in containing 100 U per vial. This inactive neurotoxin cannot be taken up by neurons but might represent an immunogenic impurity. 17 These inactive components, which have no clinical efficacy, per se, may stimulate antibody production. 11 They can reduce the efficacy of the neurotoxin by inducing immunoreactions in patients who then need to receive a higher dosage at later sessions, ultimately increasing their risk of becoming nonresponders.
Conclusion
Four BoNT/A formulations being used in Asia have shown lower neurotoxin purity and specific potency but higher neurotoxin protein concentrations than Xeomin in this study. Although Botulax and Nabota had more neurotoxin than Xeomin in an equivalent volume, they contained greater amounts of inactive neurotoxin. In addition, although Meditoxin and Relatox had slightly more neurotoxin than Xeomin, both contained greater amounts of inactive neurotoxin. In the future, it will be necessary to conduct a comparative study on the efficacy, effective duration, and safety profile of all neurotoxin products, particularly on the incidence of secondary treatment failures due to antibody formation in patients undergoing long-term treatment with BoNT/A. Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is included on PubMed. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors
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